Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Semler Scientific, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Semler Scientific securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Disclosure and Market Reaction - Semler Scientific filed its 2024 annual report on Form 10-K with the SEC, revealing that it had begun initial settlement discussions with the DOJ but ceased those discussions on February 11, 2025 [3]. - Following this disclosure, Semler Scientific's stock fell over 9% on the next trading day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4].

Core Viewpoint - A class action lawsuit has been filed against DoubleVerify Holdings, Inc. for misleading statements and failure to disclose critical information regarding its business operations and competitive position during the Class Period from November 10, 2023, to February 27, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, limiting the company's technological capabilities and competition with platforms like Meta and Amazon [5]. - It is alleged that DoubleVerify's high-margin Activation Services faced significant development costs and time delays, impacting monetization efforts [5]. - The lawsuit states that DoubleVerify's competitors were better positioned to integrate AI into their offerings, adversely affecting DoubleVerify's profitability [5]. Group 2: Investor Information - Investors who purchased DoubleVerify common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. - A lead plaintiff must be appointed by July 21, 2025, to represent the interests of other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing shareholder interests [4].

Core Viewpoint - A securities class action lawsuit has been filed against UroGen Pharma Ltd. due to significant share price decline following FDA concerns regarding the company's drug application for UGN-102 [1][2]. Group 1: Lawsuit Details - The lawsuit, Cockrell v. UroGen Pharma Ltd., seeks to represent investors who acquired UroGen securities between July 27, 2023, and May 15, 2025 [1]. - The litigation focuses on UroGen's disclosures about its communications with the FDA regarding the UGN-102 NDA, particularly the design of the pivotal trial ENVISION [3][4]. Group 2: FDA Concerns - The FDA's briefing document indicated that UroGen was advised to conduct a randomized trial for UGN-102 due to concerns about efficacy interpretation and safety data [5]. - The FDA noted that the ENVISION trial lacked a concurrent control arm, making it difficult to interpret primary endpoints such as complete response and duration of response [5]. Group 3: Impact on Share Price - Following the FDA's publication of the briefing document, UroGen's share price experienced a sharp decline on May 16, 2025, leading to substantial losses for investors [2][5]. - On May 21, 2025, it was reported that the ODAC voted 5 to 4 against the risk/profile of UGN-102, further impacting investor confidence [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Eagle Bancorp, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders of Eagle Bancorp may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2]. - Investors can join the prospective class action by submitting a form or contacting the law firm directly for more information [2]. Group 2: Financial Performance and Market Reaction - Eagle Bancorp's Q1 2025 results, announced on April 23, 2025, showed a significant miss on both earnings per share (EPS) and revenue compared to forecasts, leading to an 11.3% drop in stock price on April 24, 2025 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone, and has consistently been recognized for its success in this field [4].

Core Viewpoint - A securities class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly making false or misleading statements regarding its business operations and the commercialization of its product, Amtagvi, during the class period from May 9, 2024, to May 8, 2025 [1][3]. Company Overview - Iovance is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for metastatic melanoma and other solid tumor cancers [2]. - The company's primary product, Amtagvi, is a tumor-derived autologous T-cell immunotherapy approved by the FDA on February 16, 2024, and launched commercially on February 20, 2024 [2]. Allegations in the Class Action - The class action claims that during the class period, the defendants failed to disclose issues such as: - New Authorized Treatment Centers (ATCs) facing longer timelines to begin patient treatment with Amtagvi [3]. - Ineffectiveness of the sales team and new ATCs in identifying and selecting patients, leading to higher patient drop-offs [3]. - Resulting higher costs and lower revenue due to ATCs not keeping pace with manufactured product [3]. - Misleading positive statements about the company's business and prospects [3]. Financial Impact - On May 8, 2025, Iovance reported a significant decline in quarterly total product revenue to $49.3 million from $73.7 million in the previous quarter [4]. - The company revised its FY25 total product revenue guidance down from $450 million-$475 million to $250 million-$300 million, citing recent launch dynamics of Amtagvi [4]. - Following this announcement, Iovance's share price dropped by $1.42, or 44.8%, closing at $1.75 per share on May 9, 2025, with unusually high trading volume [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1]. Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by July 7, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking and operational inefficiencies that were not disclosed, leading to misleading positive statements about the company's prospects [5]. - The lawsuit asserts that these undisclosed issues resulted in damages to investors when the true situation became known [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of SelectQuote, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Investigation and Class Action - Shareholders who purchased SelectQuote securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to SelectQuote [2]. Group 2: Allegations and Stock Impact - SelectQuote was charged by the U.S. Department of Justice for allegedly paying hundreds of millions of dollars in illegal kickbacks to brokers from 2016 to 2021 in exchange for enrollments into Medicare Advantage plans [3]. - Following the announcement of these charges, SelectQuote's stock experienced a significant decline of 19.2% on May 1, 2025 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BigBear.ai Holdings, Inc. securities between March 31, 2022, and March 25, 2025, of the June 10, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against BigBear.ai, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - Investors wishing to serve as lead plaintiff must file with the court by June 10, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that BigBear.ai made false and misleading statements regarding its accounting practices, particularly related to the 2026 Convertible Notes [4] - Specific allegations include deficient accounting review policies, improper accounting for the 2026 Convertible Notes, and the likelihood of needing to restate financial statements [4] - The inaccuracies in financial statements are claimed to have caused investor damages when the true details became public [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Eldorado Gold Corporation due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Eldorado Gold securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Eldorado Gold [2]. Group 2: Company Update and Stock Performance - On February 5, 2025, Eldorado Gold announced delays in the Skouries Project due to labor market tightness in Greece, which has affected the availability of construction personnel [3]. - The company now expects first production at Skouries in Q1 2026 and commercial production by mid-2026 [3]. - Following this announcement, Eldorado Gold's stock price fell by 11.2% on February 6, 2025 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm was ranked No. 1 for the number of securities class action settlements in 2017 and has recovered hundreds of millions of dollars for investors over the years [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Backblaze, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a report from Morpheus Research, which accused Backblaze of financial missteps and questionable accounting practices since its IPO in November 2021 [3]. - Following the release of the Morpheus Research report, Backblaze's stock experienced a decline of 2.1% on April 24, 2025 [3]. Group 2: Class Action Information - Shareholders who purchased Backblaze securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].